Скачать или смотреть #CICON24

At CICON24, the Cancer Research Institute (CRI) unveiled a bold new chapter in its leadership and the future of cancer immunotherapy. Dr. Alicia Zhou was announced as CRI's new CEO, bringing a fresh vision for equitable cancer care and personalized treatments. The conference highlighted groundbreaking advances, from neoadjuvant trials to multiomic data analysis, cellular therapies, and the impact of diet and the microbiome on cancer treatment. See exclusive photos from the sessions that are shaping the future of immunotherapy and hear from the brightest minds in our field that are laser focused on translating cutting-edge science into survival.
--
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org

Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.